Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Neoplasms 2Recurrence 1Prostatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 10Gemcitabine 8Cisplatin 7Hepatectomy 6Fluorouracil 6Radiofrequency Ablation 5Liver Transplantation 5Irinotecan 5Capecitabine 5lenvatinib 4Paclitaxel 4Neoadjuvant Therapy 4Folfox protocol 4Cetuximab 4Aspirin 4tislelizumab 3Surgical Procedures, Operative 3Nivolumab 3Carboplatin 3titanium silicide 2durvalumab 2apatinib 2Trastuzumab 2S 1 (combination) 2Leucovorin 2Lamivudine 2Introns 2Ethiodized Oil 2Drug Therapy 2DNA, Mitochondrial 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × galactomannan × Gastrointestinal × Clear all
NCT00386516 2017-08-01

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Galectin Therapeutics Inc.

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Gallbladder Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡